Pharmaceutical Investing Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19
Pharmaceutical Investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
Pharmaceutical Investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
Pharmaceutical Investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
Pharmaceutical Investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
Pharmaceutical Investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
Pharmaceutical Investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
Pharmaceutical Investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
Cannabis Investing Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs
Pharmaceutical Investing Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19
Cannabis Investing Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
